Cardiac Science 10-Q 2009 Q1 Quarterly report

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2009

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 000-51512

Cardiac Science Corporation

(Exact name of registrant as specified in its charter)

Delaware	94-3300396
(State of Incorporation)	(IRS Employer Identification No.)

3303 Monte Villa Parkway
Bothell, Washington 98021
(Address of principal executive offices)

(425) 402-2000
(Registrant’s telephone number)

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

     Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.þ Yeso No

     Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yeso Noo

      Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filero	Accelerated filerþ	Non-accelerated filero	Smaller reporting companyo
		(Do not check if a smaller reporting company)

     Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).o Yesþ No

     The number of shares outstanding of the registrant’s common stock as of May 4, 2009 was 23,138,817.

TABLE OF CONTENTS

			Page
PART I — FINANCIAL INFORMATION
	Item 1.	Financial Statements (unaudited)		3
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		15
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk		23
	Item 4.	Controls and Procedures		23
PART II — OTHER INFORMATION
	Item 1.	Legal Proceedings		24
	Item 1A.	Risk Factors		24
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		24
	Item 3.	Defaults Upon Senior Securities		24
	Item 4.	Submission of Matters to a Vote of Security Holders		24
	Item 5.	Other Information		24
	Item 6.	Exhibits		24
	SIGNATURE			25
EX-10.1
EX-10.2
EX-31.1
EX-31.2
EX-32.1
EX-32.2

Page 2 of 29

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

CARDIAC SCIENCE CORPORATION AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,			December 31,
(In thousands)	2009			2008
ASSETS
Current Assets:
Cash and cash equivalents	$	37,563		$	34,655
Accounts receivable, net of allowance for doubtful accounts of $1,318 and $1,186, respectively		23,534			31,665
Inventories		25,879			24,692
Deferred income taxes		8,381			8,366
Prepaid expenses and other current assets		2,702			3,144
Total current assets		98,059			102,522
Other assets		369			428
Machinery and equipment, net of accumulated depreciation of $15,739 and $15,190, respectively		7,013			6,994
Deferred income taxes		28,819			28,452
Intangible assets, net of accumulated amortization of $14,874 and $13,889, respectively		30,277			31,278
Investments in unconsolidated entities		492			534
Total assets	$	165,029		$	170,208
LIABILITIES AND EQUITY
Current Liabilities:
Accounts payable	$	9,910		$	12,711
Accrued liabilities		12,065			13,535
Warranty liability		3,694			3,796
Deferred revenue		6,822			7,918
Total current liabilities		32,491			37,960
Equity:
Cardiac Science Corporation shareholders’ equity:
Preferred stock (10,000,000 shares authorized), $0.001 par value, no shares issued or outstanding as of March 31, 2009 and December 31, 2008, respectively		—			—
Common stock (65,000,000 shares authorized), $0.001 par value, 23,138,817 and 22,998,364 shares issued and outstanding at March 31, 2009 and December 31, 2008, respectively		228,127			227,303
Accumulated other comprehensive loss		(179	)		(70	)
Accumulated deficit		(96,068	)		(95,530	)
Total Cardiac Science Corporation shareholders’ equity		131,880			131,703
Noncontrolling interests		658			545
Total equity		132,538			132,248
Total liabilities and equity	$	165,029		$	170,208

     The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 3 of 29

CARDIAC SCIENCE CORPORATION AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended
	March 31,
(In thousands, except share and per share data)	2009			2008
Revenues:
Products	$	35,265		$	44,339
Service		4,399			4,620
Total revenues		39,664			48,959
Cost of Revenues:
Products		16,738			21,532
Service		3,047			3,229
Total cost of revenues		19,785			24,761
Gross profit		19,879			24,198
Operating Expenses:
Research and development		3,471			3,863
Sales and marketing		11,198			12,189
General and administrative		5,616			5,125
Total operating expenses		20,285			21,177
Operating income (loss)		(406	)		3,021
Other Income (Loss):
Interest income		13			115
Other income (loss), net		(148	)		211
Total other income (loss)		(135	)		326
Income (loss) before income tax benefit (expense)		(541	)		3,347
Income tax benefit (expense)		166			(1,240	)
Net income (loss)		(375	)		2,107
Less: Net income attributable to noncontrolling interests		(163	)		(53	)
Net income (loss) attributable to Cardiac Science Corporation	$	(538	)	$	2,054
Net income (loss) per share attributable to Cardiac
Science Corporation:
Basic	$	(0.02	)	$	0.09
Diluted	$	(0.02	)	$	0.09
Weighted average shares outstanding:
Basic		23,056,214			22,795,693
Diluted		23,056,214			23,312,933

     The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 4 of 29

CARDIAC SCIENCE CORPORATION AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months Ended
	March 31,
(In thousands)	2009			2008
Operating Activities:
Net income (loss)	$	(375	)	$	2,107
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation		659			558
Depreciation and amortization		1,525			1,609
Deferred income taxes		(367	)		1,170
Changes in operating assets and liabilities, net of businesses acquired:
Accounts receivable, net		7,987			(3,001	)
Inventories		(1,241	)		(608	)
Prepaid expenses and other assets		428			(563	)
Accounts payable		(2,339	)		1,621
Accrued liabilities		(1,336	)		(1,339	)
Warranty liability		(102	)		236
Deferred revenue		(1,096	)		670
Net cash provided by operating activities		3,743			2,460
Investing Activities:
Maturities of short-term investments		—			350
Purchases of machinery and equipment		(885	)		(434	)
Proceeds from repayment of note		73			—
Cash paid for acquisitions		(54	)		(156	)
Net cash used in investing activities		(866	)		(240	)
Financing Activities:
Proceeds from exercise of stock options and issuance of shares under employee stock purchase plan		234			173
Minimum tax withholding on restricted stock awards		(97	)		(62	)
Net cash provided by financing activities		137			111
Effect of exchange rate changes on cash and cash equivalents		(106	)		—
Net change in cash and cash equivalents		2,908			2,331
Cash and cash equivalents, beginning of period		34,655			20,159
Cash and cash equivalents, end of period	$	37,563		$	22,490

     The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 5 of 29

CARDIAC SCIENCE CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies

   Organization and Description of Business

     Cardiac Science Corporation (the “Company”) develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (“AEDs”), electrocardiograph systems, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (“HIS”), electronic medical record (“EMR”), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. The Company is the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^®brands and is headquartered in Bothell, Washington. The Company distributes its products in nearly 100 countries worldwide, with operations in North America, Europe, and Asia.

     Basis of Presentation

     The condensed consolidated financial statements present the financial condition and results of operations of the Company on a consolidated basis. All intercompany accounts and transactions have been eliminated. The condensed consolidated balance sheet dated March 31, 2009, the condensed consolidated statements of operations for the three month periods ended March 31, 2009 and 2008 and the condensed consolidated statements of cash flows for the three month periods ended March 31, 2009 and 2008 have been prepared by the Company and are unaudited. The condensed consolidated balance sheet dated December 31, 2008 was derived from the Company’s audited financial statements. Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The notes to the audited consolidated financial statements included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2008 provide a summary of significant accounting policies and additional financial information that should be read in conjunction with this report.

     In the opinion of management, all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position of the Company for the interim periods presented, have been made. The results of operations for such interim periods are not necessarily indicative of the results for the full year or any future period. In the opinion of management, these unaudited condensed consolidated financial statements include all adjustments of a normal and recurring nature necessary for a fair statement of the information for each period contained therein. Certain reclassifications have been made to prior periods to conform to the current period presentation. Specifically, we have made adjustments as a result of the adoption of a recent accounting standard, Statement of Financial Accounting Standard (“SFAS”) 160, “Noncontrolling Interests in Consolidated Financial Statements” (“SFAS 160”) effective January 1, 2009. As a result of the adoption of SFAS 160, we have reclassified $545,000 of minority interests previously classified in the mezzanine section (after total liabilities and before shareholders’ equity) as of December 31, 2008 to noncontrolling interests within “Equity” on our unaudited condensed consolidated balance sheets. We have also modified the format of the unaudited condensed consolidated statements of operations to conform to the disclosure requirements of the Standard for all periods presented. Also effective January 1, 2009, we adopted Emerging Issues Task Force (“EITF”) Topic No. D-98, “Classification and Measurement of Redeemable Securities” (“EITF D-98”); however the adoption of EITF D-98 had no impact on our financial position, results of operations or cash flows because none of the noncontrolling interests recognized in our condensed consolidated balance sheets have any redemption features that fall into the scope of this Issue. See Note 2 for further discussion on the adoption of SFAS 160.

     Use of Estimates

     The preparation of the consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the periods reported. These estimates include the collectibility of accounts receivable, the recoverability of inventory, the adequacy of warranty liabilities, the valuation of stock awards, the fair value of patent rights, intra-period tax allocation, the realizability of investments, the realizability of deferred tax assets and valuation and useful lives of tangible and intangible assets, including goodwill among others. The market for the Company’s products is characterized by intense competition, rapid technological development and frequent new product introductions, all of which could affect the future realizability of the Company’s assets. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.

Page 6 of 29

     Net Income (Loss) Per Share

     In accordance with SFAS No. 128, “Computation of Earnings Per Share” (“SFAS 128”) basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income (loss) attributable to Cardiac Science Corporation by the weighted average number of common and dilutive common equivalent shares outstanding during the period. Common equivalent shares consist of shares issuable upon the exercise of stock options, non-vested stock awards, warrants and issuance of shares under the Employee Stock Purchase Plan (“ESPP”) using the treasury stock method. Common equivalent shares are excluded from the calculation if their effect is antidilutive.

     The following table sets forth the computation of basic and diluted net income (loss) attributable to Cardiac Science Corporation per share:

	March 31,
(in thousands, except share data)	2009			2008
Numerator:
Net income (loss) attributable to Cardiac Science Corporation	$	(538	)	$	2,054
Denominator:
Weighted average shares for basic calculation		23,056,214			22,795,693
Incremental shares from employee stock options, non-vested stock awards and ESPP		—			517,240
Weighted average shares for diluted calculation		23,056,214			23,312,933

     The following table sets forth the number of antidilutive shares issuable upon exercise of stock options, non-vested stock awards, ESPP and warrants excluded from the computation of diluted net income (loss) attributable to Cardiac Science Corporation per share:

	Three Months Ended
	March 31,
	2009		2008
Antidilutive shares issuable upon exercise of stock options		3,000,194		2,588,292
Antidilutive shares issuable upon exercise of warrants		212,776		246,609
Antidilutive shares related to non-vested stock awards and ESPP		383,907		341,561
Total		3,596,877		3,176,462

     Customer and Vendor Concentrations

     The following table summarizes the customers accounting for 10% or more of total revenues:

	Three Months Ended
	March 31,
Customer	2009		2008
Nihon Kohden Corporation		*		14	%
Customer 2		*		11	%

* Did not exceed 10%.

     For the three month periods ended March 31, 2009 and 2008, we had one vendor which accounted for 13% and 17%, respectively, of purchases during these periods. Although components are available from other sources, a key vendor’s inability or unwillingness to supply components in a timely manner or on terms acceptable to the Company could adversely affect the Company’s ability to meet customers’ demands.

     Recently Adopted Accounting Pronouncements

     In April 2008, the Financial Accounting Standards Board (“FASB”) issued FASB Staff Position FAS 142-3, “Determination of the Useful Life of Intangible Assets” (“FSP FAS 142-3”), which amends the factors that should be considered in renewal or extension assumptions used to determine the useful life of a recognized intangible asset under FASB Statement 142, Goodwill and Other Intangible Assets. This statement also establishes disclosure requirements designed to

Page 7 of 29

assess the extent to which the expected future cash flows associated with the asset are affected by the entity’s intent and/or ability to renew or extend the arrangement. The Company adopted FSP FAS 142-3 in the first quarter of 2009. The adoption of this Standard did not have a material impact on the Company’s financial position or results of operations.

     In March of 2008, the FASB issued Statement of Financial Accounting Standards (“SFAS”) 161, “Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement 133” (“SFAS 161”). SFAS 161 requires entities to provide greater transparency about how and why the entity uses derivative instruments, how the instruments and related hedged items are accounted for under FASB Statement 133, and how the instruments and related hedged items affect the financial position, results of operations, and cash flows of the entity. The Company adopted SFAS 161 in the first quarter of 2009. The adoption of this Standard did not have a material impact on the Company’s financial position or results of operations.

     In December 2007, the FASB issued SFAS 141R, “Business Combinations” (“SFAS 141R”), which establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in an acquiree, including the recognition and measurement of goodwill acquired in a business combination. SFAS No. 141R, as amended by FSP 141-1 issued in April 2009, requires the acquiring entity in a business combination to recognize all (and only) the assets acquired and liabilities assumed in the transaction and establishes the acquisition-date fair value as the measurement objective for all assets acquired and liabilities assumed in a business combination. The Company adopted the provisions of SFAS 141R and FSP No. 141-1 beginning in the first quarter of 2009. In the first quarter of 2009, the Company had no transactions that would be accounted for under this Standard; therefore the adoption of this Standard had no impact on the Company’s financial position or results of operations.

     In September 2006, the FASB issued SFAS 157, “Fair Value Measurements” (“SFAS 157”), which establishes a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. In February 2008, the FASB issued FASB Staff Position FAS 157-2, “Effective Date of FASB Statement 157” (“FSP FAS 157-2”), which allows for the deferral of the adoption date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company adopted SFAS 157 for the assets and liabilities within the scope of FSP FAS 157-2 in the first quarter of 2009. Refer to Note 13, Fair Value Measurements, of this Form 10-Q for our disclosures pursuant to the effective portion of SFAS 157. The adoption of SFAS 157 for those assets and liabilities within the scope of FSP FAS 157-2 did not have a material impact on the Company’s financial position or results of operations.

     In June 2008, the FASB ratified EITF Issue 07-5, “Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock” (“EITF 07-5”). Paragraph 11(a) of Statement of Financial Accounting Standard No 133, Accounting for Derivatives and Hedging Activities (“SFAS 133”) specifies that a contract that would otherwise meet the definition of a derivative, but is both (a) indexed our own stock and (b) classified in stockholders’ equity in the statement of financial position would not be considered a derivative financial instrument. EITF 07-5 provides a new two-step model to be applied in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock, including evaluating the instrument’s contingent exercise and settlement provisions, and thus able to qualify for the SFAS 133 paragraph 11(a) scope exception. It also clarifies the impact of foreign-currency-denominated strike prices and market-based employee stock option valuation instruments on the evaluation. The Company adopted EITF issue 07-5 in the first quarter of 2009. The adoption of EITF 07-5 did not have a material impact on the Company’s financial position or results of operations.

     2. Equity and Comprehensive Income (Loss)

     In December 2007, the FASB issued SFAS 160, which amends Accounting Research Bulletin (“ARB”) 51, “Consolidated Financial Statements” (“ARB 51”). This Standard requires a noncontrolling interest in a subsidiary (previously referred to as “minority interests”) to be reported as equity on our unaudited condensed consolidated balance sheets separate from the parent’s equity. The Standard also requires transactions that do not result in the deconsolidation of the subsidiary be recorded as equity transactions, while those transactions that do result in a change from noncontrolling to controlling ownership or a deconsolidation of the subsidiary be recorded in net income (loss) with the gain or loss measured at fair value. SFAS 160 is effective January 1, 2009 and was applied prospectively with the exception of presentation and disclosure requirements which shall be applied retrospectively for all periods presented.

     The Company computes comprehensive income (loss) in accordance with SFAS 130, “Reporting Comprehensive Income” (“SFAS 130”). SFAS 130 establishes standards for the reporting and display of comprehensive income or loss and its components in the financial statements.

     For the Company, components of other comprehensive income (loss) consist of unrealized gains and losses on available-for-sale securities, net of related income tax effects and translation gains and losses related to consolidation of financial statements from foreign subsidiaries and joint ventures.

Page 8 of 29

     The following table reflects the changes in equity attributable to both Cardiac Science Corporation and the noncontrolling interests of the subsidiaries in which we have a majority, but not total, ownership interest.

	Attributable to
	Cardiac Science			Noncontrolling			Total
(in thousands)	Corporation			Interests			Equity
Equity at December 31, 2008	$	131,703		$	545		$	132,248
Comprehensive income (loss):
Net income (loss)		(538	)		163			(375	)
Unrealized gains (losses) on available for sale securities, net of related tax of $14		(28	)		—			(28	)
Foreign currency translation adjustments		(81	)		(50	)		(131	)
Comprehensive income (loss)		(647	)		113			(534	)
Stock-based transactions and compensation expense under employee benefit plans		824			—			824
Equity at March 31, 2009	$	131,880		$	658		$	132,538
Equity at December 31, 2007	$	227,271		$	127		$	227,398
Comprehensive income:
Net income		2,054			53			2,107
Unrealized gains (losses) on available for sale securities, net of related tax of $34		(59	)		—			(59	)
Foreign currency translation adjustments		(3	)		—			(3	)
Comprehensive income		1,992			53			2,045
Stock-based transactions and compensation expense under employee benefit plans		676			—			676
Equity at March 31, 2008	$	229,939		$	180		$	230,119

3. Segment Reporting

     The Company follows the provisions of SFAS 131, “Disclosures about Segments of an Enterprise and Related Information” (“SFAS 131”) which established standards for reporting information about operating segments in annual financial statements and requires selected information about operating segments to be reported in interim financial reports filed with the SEC. It also established standards for related disclosures about products and services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses whose separate financial information is available and is evaluated regularly by the Company’s chief operating decision makers, or decision making group, to perform resource allocations and performance assessments.

     The Company’s chief operating decision makers are the Chief Executive Officer and other senior executive officers of the Company. Based on evaluation of the Company’s financial information, management believes that the Company operates in one reportable segment with its various cardiology products and services.

     The Company’s chief operating decision makers evaluate revenue performance of product lines, both domestically and internationally. However, operating, strategic and resource allocation decisions are based primarily on the Company’s overall performance in its operating segment.

     The following table summarizes revenues by product line:

	Three Months Ended
	March 31,
(in thousands)	2009		2008
Defibrillation products	$	22,938	$	26,617
Cardiac monitoring products		12,327		17,722
Service		4,399		4,620
Total	$	39,664	$	48,959

Page 9 of 29

     The following table summarizes revenues, which are attributed based on the geographic location of the customers:

	Three Months Ended
	March 31,
(in thousands)	2009		2008
Domestic	$	25,864	$	32,221
Foreign		13,800		16,738
Total	$	39,664	$	48,959

     Foreign revenue includes $3,659,000 and $6,644,000 attributed to Nihon Kohden Corporation in Japan for the three months ended March 31, 2009 and 2008, respectively.

     Substantially all intangible assets are domestic. Long-lived assets located outside of the United States are not material.

4. Restructuring Costs

     On January 14, 2009, the Company announced the implementation of a restructuring plan which included a 12% reduction in work force, primarily impacting the Company’s product development, manufacturing, and customer service organizations. The restructuring was implemented in order to realign the Company’s cost structure and become more flexible and efficient in operations. Additionally, as the Company has established a historical practice of providing similar termination benefits, it was determined that the restructuring plan was an ongoing benefit arrangement, rather than a one time termination benefit. The Company recorded severance charges of approximately $1,203,000 in the fourth quarter of 2008 as management, having the appropriate authority, determined the amount of benefits were probable and estimable as of December 31, 2008.

     During the three month period ended March 31, 2009, cash severance payments were made in the amount of $888,000 and a liability for remaining severance charges of $51,000 is included in accrued liabilities in the condensed consolidated balance sheet as of March 31, 2009.

5. Inventories

     Inventories are valued at the lower of cost, on an average cost basis, or market and were comprised of the following:

	March 31,		December 31,
(in thousands)	2009		2008
Raw materials	$	20,016	$	20,871
Finished goods		5,863		3,821
Total inventories	$	25,879	$	24,692

     We perform a detailed analysis of our inventories on a quarterly basis, or more frequently should circumstances arise. Such circumstances could include, but would not be limited to, changes in a product bill of material due to design or quality improvements, product failures related to faulty or defective materials, decisions regarding product life cycles, and the Company’s ability to sell refurbished products, among others. This analysis is performed to ensure inventory items are carried at the lower of cost, on a weighted average basis, or market, and that we have adequately reserved any excess and/or obsolete items in inventory.

Page 10 of 29

6. Intangible Assets

     The following table sets forth the balances of intangible assets at March 31, 2009 (in thousands):

				Accumulated
	Useful life	Cost		Amortization			Net
Intangible assets not subject to amortization:
Burdick trade name		$	3,400	$	—		$	3,400
Cardiac Science trade name			11,380		—			11,380
Cardiac Science Deutschland trade name			171		—			171
Total intangible assets not subject to amortization			14,951		—			14,951
Intangible assets subject to amortization:
Cardiac Science customer relationships	5 years		8,650		(6,199	)		2,451
Cardiac Science developed technology	8 years		11,330		(5,075	)		6,255
Burdick distributor relationships	10 years		1,400		(875	)		525
Burdick developed technology	7 years		860		(768	)		92
Patents and patent applications	5-10 years		960		(925	)		35
Patent rights	13 years		7,000		(1,032	)		5,968
Total intangible assets subject to amortization			30,200		(14,874	)		15,326
Total		$	45,151	$	(14,874	)	$	30,277

     The Company’s estimated expense for the amortization of intangibles for each full year ended December 31 is summarized as follows (in thousands):

2009	$	3,957
2010		3,258
2011		2,104
2012		2,102
2013		1,483
Thereafter		3,410

7. Credit Facility

     The Company has a $10.0 million line of credit with Silicon Valley Bank with minimal restrictions on the amount eligible for borrowing. Substantially all of our current assets are pledged as collateral for the line of credit. This line of credit bears interest, based on our quarterly adjusted EBITDA, at the lender’s prime rate or LIBOR plus 1.75%. At March 31, 2009 and 2008 the Company did not have any borrowings under this or any other line of credit.

8. Warranty Liability

     Changes in the warranty liability for the three months ended March 31, 2009 were as follows:

	Three months ended
(in thousands)	March 31, 2009
Warranty liability, beginning of the period	$	3,796
Charged to product cost of revenues, net		884
Warranty expenditures		(986	)
Warranty liability, end of the period	$	3,694

     9. Stock-Based Compensation Plans

     The Company maintains several equity incentive plans under which it may grant non-qualified stock options, incentive stock options and non-vested stock awards to employees, non-employee directors and consultants. The Company also has an Employee Stock Purchase Plan (“ESPP”).

Page 11 of 29

     The fair value of each option grant and ESPP purchase is estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions and the fair value of the non-vested stock awards is calculated based on the market value of the shares awarded at date of grant:

	Three Months Ended			Three Months Ended
	March 31, 2009			March 31, 2008
Stock options plans:
Volatility		52.6	%		48.4	%
Expected term (years)		6.25			6.25
Risk-free interest rate		2.3	%		3.4	%
Expected dividend yield		—			—
Fair value of options granted	$	1.62		$	4.23
Employee stock purchase plan:
Volatility		40.0	%		27.0	%
Expected term (years)		0.5			0.5
Risk-free interest rate		2.1	%		4.5	%
Expected dividend yield		—			—
Fair value of employee stock purchase rights	$	1.73		$	2.01
Non-vested stock:
Fair values of non-vested stock awards granted	$	2.87-3.75		$	8.25-9.03

     The Company estimates the expected term of share options in accordance with SFAS 123(R) “Share Based Payments” (“SFAS 123R”).

     The following shares of common stock have been reserved for issuance under the Company’s stock-based compensation plans as of March 31, 2009:

Outstanding shares – 2002 Plan	2,163,882
Outstanding shares – 1997 Plan	836,312
Stock options available for grant	1,251,216
Outstanding non-vested stock awards	283,657
Employee stock purchase plan shares available for issuance	708,035
Total common shares reserved for future issuance	5,243,102

     2002 Plan —The Company’s 2002 Stock Incentive Plan (the“2002 Plan”) allows the Company to issue awards of incentive or nonqualified stock options, shares of common stock or units denominated in common stock (including non-vested stock awards), all of which may be subject to restrictions. The 2002 Plan authorizes annual increases in shares for issuance equal to the lesser of (i) 526,261 shares, (ii) 3% of the number of shares of common stock outstanding on a fully diluted basis as of the end of the Company’s immediately preceding fiscal year, and (iii) a lesser amount established by the Company’s board of directors. Any shares from increases in previous years that are not issued will continue to be included in the aggregate number of shares available for future issuance.

     The following table summarizes information about the 2002 Plan option activity during the three months ended March 31, 2009:

	Shares
	Subject to
	Options
Outstanding, December 31, 2008		2,063,065
Granted		160,000
Exercised		(32,508	)
Forfeited or expired		(26,675	)
Outstanding, March 31, 2009		2,163,882
Exercisable, March 31, 2009		1,599,632

Page 12 of 29

     Non-vested Stock Awards —As part of the 2002 Plan, the stock award program offers employees the opportunity to earn shares of the Company’s stock over time, rather than options that give employees the right to purchase stock at a set price. Non-vested stock awards require no payment from the employee, with the exception of employee related federal taxes.

     The following table summarizes information about the non-vested stock award activity during the three months ended March 31, 2009:

	Shares
Non-vested balance, December 31, 2008		388,002
Granted		24,853
Vested		(95,124	)
Forfeited		(34,074	)
Non-vested balance, March 31, 2009		283,657

     1997 Plan —The Company’s 1997 Stock Option/Stock Issuance Plan (the “1997 Plan”) provided for the granting of incentive or nonqualified stock options to employees of the Company, including officers, and nonqualified stock options to employees, including officers and directors of the Company, as well as to certain consultants and advisors. Shares authorized under the 1997 Plan are subject to adjustment upon the occurrence of certain events, including, but not limited to, stock dividends, stock splits, combinations, mergers, consolidations, reorganizations, reclassifications, exchanges, or other capital adjustments. The 1997 plan expired in 2007. Accordingly, no future grants are allowed under the 1997 Plan. Previous awards under the 1997 Plan will continue to be outstanding until they are exercised, expire or are forfeited.

     The following table summarizes information about the 1997 Plan option activity during the three months ended March 31, 2009:

	Shares
	Subject to
	Options
Outstanding, December 31, 2008		836,312
Forfeited or expired		—
Outstanding, March 31, 2009		836,312
Exercisable, March 31, 2009		810,062

     Employee Stock Purchase Plan —The Company has an ESPP which was established by Quinton in 2002 and was assumed by the Company in connection with the merger transaction. The ESPP permits eligible employees to purchase common stock through payroll deductions. Shares of our common stock may presently be purchased by employees at three month intervals at 85% of the fair market value on first day of the offering period or the last day of each three month purchase period. Employees may purchase shares having a value not exceeding 15% of their gross compensation during an offering period, not to exceed 525 shares during an offering period. The Company initially reserved 175,420 shares for issuance under the ESPP. In addition, the ESPP authorizes annual increases in shares for issuance equal to the lesser of (i) 175,420 shares, (ii) 2% of the number of shares of common stock outstanding on a fully diluted basis as of the end of the Company’s immediately preceding fiscal year, and (iii) a lesser amount established by the Company’s board of directors. Any shares from increases in previous years that are not actually issued will continue to be included in the aggregate number of shares available for future issuance.

     The Company issued 40,951 and 23,499 shares of common stock during the three months ended March 31, 2009 and 2008, respectively, in connection with the ESPP and received total proceeds of $127,000 and $168,000, respectively.

10. Commitments and Contingencies

     Other Commitments

     As of March 31, 2009, the Company had purchase obligations of approximately $38,191,000 consisting of outstanding purchase orders issued in the normal course of business.

Page 13 of 29

     Guarantees and Indemnities

     During its normal course of business, the Company has made certain guarantees, indemnities and commitments under which it may be required to make payments in relation to certain transactions. These indemnities include intellectual property and other indemnities to the Company’s customers and suppliers in connection with the sales of its products, and indemnities to directors and officers of the Company to the maximum extent permitted under the laws of the State of Delaware. Historically, the Company has not incurred any losses or recorded any liabilities related to performance under these types of indemnities.

     Legal Proceedings

     The Company is subject to various legal proceedings arising in the normal course of business. In the opinion of management, the ultimate resolution of these proceedings is not expected to have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

11. Income Taxes

     The Company applies the provisions of FASB Interpretation 48, “Accounting for Uncertainty in Income Taxes — an interpretation of FASB 109” (“FIN 48”). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in the Company’s financial statements in accordance with SFAS 109, “Accounting for Income Taxes” (“SFAS 109”). The interpretation established guidelines for recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. Based on management’s review of the Company’s tax positions, the Company had no significant unrecognized tax benefits as of March 31, 2009 and December 31, 2008.

     The Company is subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions as well as federal, state and foreign filings related to Quinton and CSI. As a result of the net operating loss carryforwards, substantially all tax years are open for U.S. federal and state income tax matters. Foreign tax filings are open for years 2001 forward.

     The Company’s continuing practice is to recognize interest and/or penalties related to income tax matters in income tax expense. At March 31, 2009, the Company had no accrued interest related to uncertain tax positions and no accrued penalties.

12. Derivatives

      Effective January 1, 2009, the Company adopted the disclosure requirements of SFAS 161, “Disclosures about Derivative Instruments and Hedging Activities-an Amendment of FASB Statement No. 133” (“SFAS 161”). The Company follows SFAS 133, “Accounting for Derivative Instruments and Hedging Activities (as amended)” (“SFAS 133”), in accounting for derivative and hedging activities. The Company is exposed to foreign currency exchange-rate fluctuations in the normal course of its business, which the Company manages through the use of forward foreign exchange contracts. Forward foreign exchange contracts (instruments) are used to hedge the impact of fluctuations of foreign exchange on certain assets or liabilities denominated in a currency other than the functional currency of the Company or its subsidiaries. Currently, these instruments do not qualify for derivative hedge accounting. The Company uses these instruments to mitigate risk and does not intend to engage in speculative transactions. The forward foreign exchange contracts are entered into by the Company primarily to hedge foreign denominated accounts receivable and foreign cash holdings. These contracts do not contain any credit-risk-related contingent features.

     The Company seeks to manage the counterparty risk associated with these forward foreign exchange contracts by limiting transactions to counterparties with which the Company has an established banking relationship. In addition, the contracts are limited to a time period of less than one year, generally three months or less.

     During the three month periods ended March 31, 2009 and 2008, these forward foreign exchange contracts resulted in net realized gains of $0.1 million and unrealized losses of $0.1 million, respectively. The realized and unrealized gains and losses were partially offset by realized and unrealized gains and losses on foreign denominated accounts receivable and foreign cash holdings in the same periods. Realized and unrealized gains and losses related to forward foreign exchange contracts are recorded in other income (loss), net. As of March 31, 2009 and December 31, 2008, there were no unsettled forward foreign exchange contracts outstanding. At March 31, 2009, the Company had a liability of $0.2 million related to realized losses on settled forward foreign exchange contracts that it owed the counterparty included in accrued liabilities and at December 31, 2008, the Company had an asset of $0.3 million related to realized gains on settled forward foreign exchange contracts owed by the counterparty included in prepaid expenses and other current assets.

13. Fair Value Measurement

     The Company adopted SFAS 157 as of January 1, 2008, with the exception of the application of the Statement to non-recurring fair value measurement relating to nonfinancial assets and nonfinancial liabilities. The Company adopted the provisions of SFAS 157 related to these nonfinancial assets and nonfinancial liabilities effective January 1, 2009 in accordance with FSP 157-2. This adoption did not have a material impact on the Company’s financial position, results of operations or cash flows.

     SFAS 157 establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value. Classification of a financial asset or liability within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

     The Company’s assets and liabilities that are carried at fair value and are accounted for under SFAS 157 are recorded on the balance sheet in cash equivalents and investments in unconsolidated entities.

Page 14 of 29

     The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2009:

	Total carrying		Quoted prices in
	value at March		active markets
(in thousands of dollars)	31, 2009		(Level 1)
Assets:
Cash equivalents	$	26,599	$	26,599
Investments in unconsolidated entities	$	412	$	412

14. Subsequent Event

     On April 2, 2009, Biotel, Inc. announced that it had signed a definitive merger agreement with CardioNet, Inc. to be acquired in an all cash transaction valued at approximately $14.0 million, or $4.82 per share of Biotel stock. At March 31, 2009, the Company held 180,269 shares of Biotel stock valued at $1.78 per share. The Company accounts for these shares as available for sale, and recorded the fair value of the shares of $322,000 at March 31, 2009 as investments in unconsolidated entities in the accompanying condensed consolidated balance sheet.

     The agreement is subject to Biotel, Inc. shareholder approval and is expected to close in mid-2009. Should the deal close as expected, the Company will receive approximately $870,000 in cash based upon the shares held as of March 31, 2009. The Company would recognize a realized gain of approximately $500,000 based on the historical cost of approximately $2.05 per share, or approximately $370,000.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     This Quarterly Report onForm 10-Q contains forward-looking statements relating to Cardiac Science Corporation. Except for historical information, the following discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including future results of operations or financial position, made in this Quarterly Report onForm 10-Q are forward looking. The words “believe,” “expect,” “intend,” “anticipate,” “will,” “may,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These forward-looking statements reflect management’s current expectations and involve risks and uncertainties. Our actual results could differ materially from results that may be anticipated by such forward-looking statements due to various uncertainties.

     The principal factors that could cause or contribute to such differences include, but are not limited to, the factors discussed in the section entitled “Risk Factors” in Part 1 — Item 1A of our Annual Report onForm 10-K for the year ended December 31, 2008 and those discussed elsewhere in this report. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. We undertake no obligation to revise any forward-looking statements to reflect events or circumstances that may subsequently arise. Readers are urged to review and consider carefully the various disclosures made in this report and in our other filings made with the Securities and Exchange Commission (“SEC”) that disclose and describe the risks and factors that may affect our business, prospects and results of operations.

     You should read the following discussion and analysis in conjunction with our unaudited condensed consolidated financial statements and related notes included elsewhere in this report. Operating results for the three month period ended March 31, 2009 are not necessarily indicative of future results including the full fiscal year. You should also refer to our Annual Consolidated Financial Statements, Notes thereto, and Management’s Discussion and Analysis of Financial Condition and Results of Operations and “Risk Factors” contained in our Annual Report on Form 10-K for the year ended December 31, 2008, filed with the SEC on March 16, 2009.

Page 15 of 29

     Business Overview

     We develop, manufacture, and market a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph systems (ECGs), stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (Informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. We sell a variety of related products and consumables, and provide a portfolio of training, maintenance, and support services. We are the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^®brands and are headquartered in Bothell, Washington. We distribute our products in nearly 100 countries worldwide, with operations in North America, Europe, and Asia.

     Critical Accounting Estimates and Policies

     To prepare financial statements that conform with U.S. generally accepted accounting principles, we must select and apply accounting policies and make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We base our accounting estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

     There are certain critical accounting estimates that we believe require significant judgment in the preparation of our consolidated financial statements. We consider an accounting estimate to be critical if it requires us to make assumptions because information was not available at the time or it included matters that were highly uncertain at the time we were making the estimate,and changes in the estimate or different estimates that we reasonably could have selected would have had a material impact on our financial condition or results of operations.

     Deferred Tax Assets and Income Taxes. As part of the process of preparing our consolidated financial statements, we are required to account for our income taxes. This process involves calculating our current tax obligation or refund and assessing the nature and measurements of temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities. In each period, we assess the likelihood that our deferred tax assets will be recovered from existing deferred tax liabilities or future taxable income. If required, we will recognize a valuation allowance to reduce such deferred tax assets to amounts that are more likely than not to be ultimately realized. To the extent that we establish a valuation allowance or change this allowance in a period, we adjust our tax provision or tax benefit in the statement of operations. We use our judgment to determine our provision or benefit for income taxes, and any valuation allowance recorded against our net deferred tax assets.

     Factors we consider in making such an assessment include, but are not limited to past performance, including our recent history of operating results on a GAAP basis, our recent history of generating taxable income, our history of recovering net operating loss carryforwards for tax purposes and our expectation of future taxable income, both considering our past history in predicting future results and considering current macroeconomic conditions and issues facing our industry.

     Stock-Based Compensation.As of January 1, 2006, we account for stock-based compensation in accordance with SFAS No. 123(R), “Share-Based Payment”, and apply the provisions of Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 107, “Share-Based Payment” (“SAB 107”). Under the fair value recognition provisions of this statement, share-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. Determining the fair value of share-based awards at the grant date requires judgment, including estimating future volatility, expected term and the amount of share-based awards that are expected to be forfeited. If actual results differ significantly from these estimates, stock-based compensation expense and our results of operations could be materially impacted.

     Goodwill.During the fourth quarter of 2008, we impaired the entire balance of previously acquired goodwill which totaled $107.7 million and as of March 31, 2009 and December 31, 2008 we had no goodwill recorded on our consolidated balance sheets. Previously recorded goodwill represented the excess of cost over the estimated fair value of net assets acquired in connection with acquisitions of our medical treadmill product line, Burdick, Inc. and Cardiac Science, Inc. We tested goodwill for impairment on an annual basis, and between annual tests in certain circumstances, for our single reporting unit identified for purposes goodwill impairment testing. Our reporting unit consists of general cardiology products and services. Application of the goodwill impairment test required judgment, including the identification of our reporting unit and significant assumptions related to the fair value of the reporting unit, including estimates of future cash flows, determination of appropriate discount rates, an applicable control premium and other assumptions.

     Intangible Assets.Our intangible assets are comprised primarily of trade names, developed technology, patent rights and customer relationships, all of which were acquired in our acquisition of Burdick in 2003, the merger transaction with CSI in 2005 and the cross-licensing agreement with Koninklijke Philips Electronics N.V. (“Philips”) in 2007. We use our judgment to estimate the fair value of each of these intangible assets. Our judgment about fair value is based on our expectation of

Page 16 of 29

future cash flows and an appropriate discount rate. We also use our judgment to estimate the useful lives of each intangible asset.

     We believe the Burdick, Cardiac Science and Cardiac Science Deutschland trade names have indefinite lives and, accordingly, we do not amortize these trade names. We evaluate this conclusion annually or more frequently if events and circumstances indicate that these assets might be impaired and make a judgment about whether there are factors that would limit our ability to benefit from the trade names in the future. If there were such factors, we would start amortizing the trade names over the expected remaining period in which we believe it would continue to provide benefit. With respect to our developed technology, customer relationships and patent rights, we also evaluate the remaining useful lives annually.

     We periodically evaluate whether our intangible assets are impaired. For our trade names, this evaluation is performed annually, or more frequently if events occur that suggest there may be an impairment loss, and involves comparing the carrying amount to our estimate of fair value. For intangible assets related to developed technology, customer relationships and patent rights, this evaluation would be performed if events occur that suggest there may be an impairment loss. If we conclude that any of our intangible assets are impaired, we would record a loss on our statement of operations and reduce the value of the intangible asset.

     Accounts Receivable.Accounts receivable represent a significant portion of our assets. We must make estimates of the collectability of accounts receivable. We analyze historical write-offs, changes in our internal credit policies and customer concentrations when evaluating the adequacy of our allowance for doubtful accounts. Different estimates regarding the collectability of accounts receivable may have a material impact on the timing and amount of reported bad debt expense and on the carrying value of accounts receivable.

     Valuation of Long-Lived Assets.We review long-lived assets, such as machinery and equipment, and intangible assets subject to amortization, whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. Recoverability of asset groups to be held and used is measured by a comparison of the carrying amount of an asset group to estimated undiscounted future cash flows expected to be generated by the asset group. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized on our statement of operations and as a reduction to value of the asset group on our balance sheet. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance sheet.

     Inventories.Inventories represent a significant portion of our assets. We value inventories at the lower of cost, on an average cost basis, or market. We perform a detailed analysis of our inventories on a quarterly basis, or more frequently should circumstances arise. Such circumstances could include, but would not be limited to, changes in a product bill of material due to design or quality improvements, product failures related to faulty or defective materials, decisions regarding product life cycles, and our ability to sell refurbished products, among others. Our quarterly analysis is preformed to determine whether adjustments are necessary to reduce inventory values to estimated net realizable value. We consider various factors in making this determination, including the salability of individual items or classes of items, recent sales history and predicted trends, industry market conditions and general economic conditions. Different estimates regarding the net realizable value of inventories could have a material impact on our reported net inventory and cost of sales, and thus could have a material impact on the financial statements as a whole.

     Warranty.We provide warranty service covering many of the products and systems we sell. We estimate and accrue for future costs of providing warranty service, which relate principally to the hardware components of the systems, when the systems are sold. Our estimates are based, in part, on our warranty claims history and our cost to perform warranty service. Differences could result in the amount of the recorded warranty liability and cost of sales if we made different judgments or used different estimates.

     Software Revenue Recognition.We account for the licensing of software in accordance with American Institute of Certified Public Accountants (“AICPA”) Statement of Position (“SOP”) 97-2 (“SOP 97-2”), “Software Revenue Recognition”, as amended by SOP 98-9, “Modification of SOP 97-2, Software Revenue Recognition, With Respect to Certain Transactions” (“SOP 98-9”). The application of SOP 97-2 requires judgment, including whether a software arrangement includes multiple elements, and if so, whether vendor-specific objective evidence (“VSOE”) of fair value exists for those elements. Customers may receive certain elements of our products over a period of time. These elements include post-delivery telephone support and the right to receive unspecified upgrades/enhancements (on a when-and-if available basis), the fair value of which is recognized over the service period. Changes to the elements in a software arrangement and the ability to identify VSOE of fair value for those elements could materially impact the amount of earned and unearned revenue.

     With respect to arrangements where software is considered more than incidental to the product, the vendor specific objective evidence of fair value for undelivered support is deferred and the residual fair value of delivered software is

Page 17 of 29

recognized. Revenue from software implementation services is recognized as the services are provided (based on vendor specific objective evidence of fair value). When significant implementation activities are required, we recognize revenue from software and services upon installation. We occasionally sell software and hardware upgrades on a stand alone basis.

     Revenue Recognition.Revenue from sales of hardware products is generally recognized when title transfers to the customer, typically upon shipment. Some of our customers are distributors that sell goods to third party end users. Except for certain identified distributors where collection may be contingent on distributor resale, we recognize revenue on sales of products made to distributors when title transfers to the distributor and all significant obligations have been satisfied. In making a determination of whether significant obligations have been met, we evaluate any installation or integration obligations to determine whether those obligations are inconsequential or perfunctory. In cases where the remaining installation or integration obligation is not determined to be inconsequential or perfunctory, we defer the portion of revenue associated with the fair value of the installation and integration obligation until these services have been completed.

     Distributors do not have price protection and generally do not have product return rights, except if the product is defective upon shipment or shipped in error, and in some cases upon termination of the distributor agreement. For certain identified distributors where collection may be contingent on the distributor’s resale, revenue recognition is deferred and recognized on a “sell through” or cash basis. The determination of whether sales to distributors are contingent on resale is subjective because we must assess the financial wherewithal of the distributor to pay regardless of resale. For sales to distributors, we consider several factors, including past payment history, where available, trade references, bank account balances, Dun & Bradstreet reports and any other financial information provided by the distributor, in assessing whether the distributor has the financial wherewithal to pay regardless of, or prior to, resale of the product and that collection of the receivable is not contingent on resale.

     We offer limited volume price discounts and rebates to certain distributors. Volume price discounts are on a per order basis based on the size of the order and are netted against the revenue recorded at the time of shipment. We have some arrangements that provide for volume discounts based on meeting certain quarterly or annual purchase levels. Rebates are paid quarterly or annually and are accrued for as incurred.

     We consider program management packages and training and other services as separate units of accounting and apply the provisions of Emerging Issues Task Force (“EITF”) consensus on Issue No. 00-21, “Revenue Arrangements with Multiple Deliverables” (“EITF 00-21”) when sold with an AED based on the fact that the items have value to the customer on a stand alone basis and could be acquired from another vendor. Fair value is determined to be the price at which they are sold to customers on a stand alone basis. Training revenue is deferred and recognized at the time the training occurs. AED program management services revenue, pursuant to agreements that exist with some customers pursuant to annual or multi-year terms, are deferred and amortized on a straight-line basis over the related contract period.

     We offer optional extended service contracts to customers. Fair value is determined to be the price at which they are sold to customers on a stand alone basis. Service contract revenues are recognized on a straight-line basis over the term of the extended service contracts, which generally begin after the expiration of the original warranty period. For services performed, other than pursuant to warranty and extended service contract obligations, revenue is recognized when the service is performed and collection of the resulting receivable is reasonably assured.

Page 18 of 29

Results of Operations

     Summary of Results for the Three Months Ended March 31, 2009

• We generated revenue of $39.7 million in the three months ended March 31, 2009, a decrease of approximately 19% over the three month period ended March 31, 2008, which included an overall AED decline of 14%, cardiac monitoring decline of 30% and a decline in service revenues of 5%.

• Operating loss for the three months ended March 31, 2009 was $0.4 million, compared with operating income of $3.0 million for the three months ended March 31, 2008 due primarily to lower revenue in the current period.

• We generated a net loss per share attributable to Cardiac Science Corporation of $0.02 for the three months ended March 31, 2009 compared with diluted earnings per share attributable to Cardiac Science Corporation of $0.09 for the three months ended March 31, 2008.

• We generated cash from operations of $3.7 million for the three months ended March 31, 2009 compared to cash generated from operations of $2.5 million for the three months ended March 31, 2008.

     Looking Forward

     There are a number of factors that may negatively affect revenue growth in future periods, most notably the significant downturn in the global economy, in particular in the U.S. and Japan. We continue to expect long-term growth in AED revenues over time, both domestically and overseas. However, we do not expect growth at the same level as recent years in the near term due to deteriorating global economic conditions which are having an impact on the speed of AED deployments domestically and internationally, including softness in the U.S. and Japanese markets, in particular. In addition to weak economic conditions in Japan, our operating performance in that market could be negatively impacted by our exclusive distributor’s expected introduction of new products that may erode sales of our products in that market. We believe the long-term outlook for AED sales globally is positive. However sales in the near term in the U.S. and Japan will likely be down during 2009 as compared to the same periods in the prior year. We believe our direct presence in several countries in Europe will result in continued growth in sales in these markets over time, though again we may experience softness in the near term due to weak economic conditions. We are cautious about revenue projections from the hospital defibrillator we manufacture for GE due to challenges in the global hospital market. We expect our cardiac monitoring line to ultimately grow over time

Page 19 of 29

though, again, due to the weakened global economy, our cardiac monitoring revenues may continue to be down during 2009 as compared to the same periods in the prior year. We expect that service revenue and related gross profit will remain flat or grow somewhat in 2009 and will continue to grow thereafter. Additionally, the results of our continued effort to revitalize our cardiac monitoring line and our ability to continue to capture a sizeable share of the global AED market as it rapidly evolves will be factors of our success going forward.

     We expect continued growth in gross profit over the longer term. However a number of the factors discussed above relating to revenue will negatively affect our gross profit in the near term.

     Revenues

     We derive our revenues primarily from the sale of our non-invasive cardiology products and related consumables, and to a lesser extent, from services related to these products, including training. We categorize our revenues as (1) defibrillation products, which includes our AEDs, hospital defibrillators and related accessories; (2) cardiac monitoring products, which includes capital equipment, software products and related accessories and supplies; and (3) service, which includes service contracts, CPR/AED training services, AED program management services, equipment maintenance and repair, replacement part sales and other services. We derive a portion of our service revenue from sales of separate extended maintenance arrangements. We defer and recognize these revenues over the applicable maintenance period.

     Revenues for the three months ended March 31, 2009 and 2008 were as follows:

	Three Months						Three Months
	Ended			% Change			Ended
(dollars in thousands)	March 31, 2009			2008 to 2009			March 31, 2008
Defibrillation products	$	22,938			(13.8	%)	$	26,617
% of revenue		57.8	%					54.4	%
Cardiac monitoring products		12,327			(30.4	%)		17,722
% of revenue		31.1	%					36.2	%
Service		4,399			(4.8	%)		4,620
% of revenue		11.1	%					9.4	%
Total revenues	$	39,664			(19.0	%)	$	48,959

     Defibrillation products revenue decreased 14% for the three month period ended March 31, 2009 from the comparable period in 2008 driven by declines in both domestic and international sales of 12% and 16%, respectively. The decline in domestic defibrillation sales is due largely to weakened economic conditions in the United States. The decline in international defibrillation sales is due in part to lower sales in the Japanese marketplace resulting from weak economic conditions in Japan. However, this was partially offset by increased sales in other foreign countries where we have been able to increase market share over time through increased distribution efforts and, in some cases, where we have established a direct presence within the marketplace.

     Cardiac monitoring products revenue decreased by 30% for the three month period ended March 31, 2009 from the comparable period in 2008. The decrease in our cardiac monitoring revenue is due primarily to weakness in both the worldwide hospital market as well as lower domestic sales of products for use in physician offices.

     Service revenue decreased 5% for the three month period ended March 31, 2009 from the comparable period in 2008 due primarily to lower AED training and program management services resulting from declines in defibrillation product revenues during the period.

     Gross Profit

     Gross profit is revenues less the cost of revenues. Cost of revenues consists primarily of the costs associated with manufacturing, assembling and testing our products, amortization of certain intangibles, overhead costs, compensation, including stock-based compensation and other costs related to manufacturing support and logistics. We rely on third parties to manufacture certain of our product components. Accordingly, a significant portion of our cost of revenues consists of payments to these manufacturers. Cost of service revenues consists of customer support costs, training and professional service expenses, parts and compensation. Our hardware products include a warranty period that includes factory repair services or replacement parts. We accrue estimated expenses for warranty obligations at the time products are shipped.

Page 20 of 29

      Gross profit for the three months ended 31, 2009 and 2008 was as follows:

	Three Months Ended			% Change			Three Months Ended
(dollars in thousands)	March 31, 2009			2008 to 2009			March 31, 2008
Products	$	18,631			(18.3	%)	$	22,807
% of products revenue		52.8	%					51.4	%
Service		1,248			(10.3	%)		1,391
% of service revenue		28.4	%					30.1	%
Total gross profit	$	19,879			(17.8	%)	$	24,198
% of total revenue		50.1	%					49.4	%

     Gross profit from products decreased for the three month period ended March 31, 2009 from the comparable period in 2008 due principally to lower sales volumes resulting from weakened conditions in the global economy. However, gross margin increased slightly for the three month period ended March 31, 2009 as compared to the same period in the prior year due primarily to a shift in overall product mix to a higher proportion of defibrillation products, for which gross margin is generally higher than for cardiac monitoring products.

     Gross profit from service decreased for the three month period ended March 31, 2009 from the comparable period in 2008 due principally higher service labor and other costs associated with cardiac monitoring service in the first quarter of 2009, as compared the same period during 2008.

     Operating Expenses

     Operating expenses include expenses related to research and development, sales, marketing and other general and administrative expenses required to run our business, including stock-based compensation.

     Research and development expenses consist primarily of salaries and related expenses for development and engineering personnel, fees paid to consultants, and prototype costs related to the design, development, testing and enhancement of products. We expense research and development costs as incurred.

     Sales and marketing expenses consist primarily of salaries, commissions and related expenses for personnel engaged in sales, marketing and sales support functions as well as costs associated with promotional and other marketing activities.

     General and administrative expenses consist primarily of employee salaries and related expenses for executive, finance, accounting, information technology, regulatory and human resources personnel as well as professional fees, legal fees, and other corporate expenses.

     Operating expenses for the three months ended March 31, 2009 and 2008 were as follows:

	Three Months Ended			% Change			Three Months Ended
(dollars in thousands)	March 31, 2009			2008 to 2009			March 31, 2008
Research and development	$	3,471			10.1	%	$	3,863
% of total revenue		8.8	%					7.9	%
Sales and marketing		11,198			8.1	%		12,189
% of total revenue		28.2	%					24.9	%
General and administrative		5,616			(9.6	%)		5,125
% of total revenue		14.2	%					10.5	%
Total operating expenses	$	20,285			4.2	%	$	21,177
% of total revenue		51.1	%					43.3	%

     The decrease in research and development expenses for the three month period ended March 31, 2009 from the comparable period in 2008 was due almost entirely to decreased labor costs resulting from restructuring programs implemented by the Company during the fourth quarter 2008.

Page 21 of 29

     The decrease in sales and marketing expenses for the three month period ended March 31, 2009 from the comparable period in 2008 was due in part to lower commissions related to lower total revenues, which decreased 19% from the comparable period in 2008. In addition, employee related labor and other costs decreased for the three month period ended March 31, 2009 as a result of efforts to reduce costs and prioritize spending during 2009.

     The increase in general and administrative expenses for the three month period ended March 31, 2009 from the comparable period in 2008 was due in part to increases in payroll and benefit expenses related to staffing increases in our regulatory affairs and quality assurance functions, as well as higher professional service fees and stock based compensation relating primarily to the transition of the Company’s former President and Chief Executive Officer.

     Other Income and Expense

     Interest income has decreased significantly in recent quarters as we have transitioned all of our cash equivalents to very conservative investments which have yielded very low interest rates. This decision has been made in response to the present volatility in the financial markets resulting from uncertainty surrounding current global economic conditions. For the three month periods ended March 31, 2009, we earned insignificant amounts of interest income on our cash equivalents as compared to the same period in the prior year.

     Other income (loss), net was a loss of ($0.1) million for the three month period ended March 31, 2009 as compared to income of $0.2 million during the same period in 2008. Other income (loss), net for the three month period ended March 31, 2009 consisted primarily of net foreign currency exchange losses of $0.2 million partially offset by income from royalty agreements of $0.1 million. Other income (loss), net for the three month period ended March 31, 2008 consisted primarily of income from sub-lease agreements at facilities acquired in 2005 of $0.1 million as well as net foreign currency exchange gains of $0.1 million.

     Income Taxes

     During the three month period ended March 31, 2009, we recorded an income tax benefit of $0.2 million compared to income tax expense of $1.2 million in the three month period ended March 31, 2008. Our worldwide effective tax rate for the three month period ended March 31, 2009 was a benefit of 31% as compared to a worldwide effective tax rate of 37% for the same period in the prior year. The difference in our estimated worldwide effective tax rate for the three month period ended March 31, 2009 as compared to the same period in the prior year is due largely to a discrete item in the amount of $201,000 in the first quarter of 2009 related to unfavorable tax effects of certain stock based awards which vested during the period and, to a lesser extent to differences in other factors such as pre tax income (loss) projections for 2009.

     We record our quarterly provision for income taxes based on our estimated worldwide effective tax rates for the full year, which are determined based on estimates of pre-tax income or losses for the full year, applicable rates in jurisdictions in which income and losses are expected to be generated and expected federal and state tax credits. We estimate our worldwide effective tax rate benefit for the year ended December 31, 2009 will be approximately 68% prior to any discrete items recorded during the year.

     Liquidity and Capital Resources

	Three Months Ended			% Change			Three Months Ended
(dollars in thousands)	March 31, 2009			2008 to 2009			March 31, 2008
Cash provided by operating activities	$	3,743			52.2	%	$	2,460
Cash used in investing activities		(866	)		(260.8	%)		(240	)
Cash provided by financing activities		137			23.4	%		111
Effect of exchange rates on cash and cash equivalents		(106	)		n/m			—
Total change in cash and cash equivalents	$	2,908			24.8	%	$	2,331

     Cash provided by operating activities of $3.7 million for the three month period ended March 31, 2009 resulted from our net loss of $0.4 million plus adjustments for net non-cash items included in net income of $1.8 million and a net decrease in working capital of $2.3 million. The net non-cash items included in net income related primarily to depreciation and amortization, stock-based compensation and deferred income taxes. The net decrease in working capital of $2.3 million during the period was due primarily to a reduction in accounts receivable of $8.0 million as our cash collections were higher than sales during the period. This decrease was partially offset by a reduction in operating liabilities related to accounts payable, accrued expenses and deferred revenue totaling $4.8 million. Cash provided by operating activities of $2.5 million

Page 22 of 29

for the three month period ended March 31, 2008 resulted from our net income of $2.1 million plus adjustments for net non-cash items included in net income of $3.3 million and a net increase in working capital of $3.0 million. The net non-cash items included in net income related primarily to depreciation and amortization, stock-based compensation and deferred income taxes. The net increase in working capital of $3.0 million was due primarily to increases in accounts receivable and inventory totaling $3.6 million, partially offset by increases in operating liabilities resulting from an increase of deferred revenue of $0.7 million related to product shipments that were not delivered by March 31, 2008.

     We anticipate that cash provided by operations will decrease in 2009 as compared to cash provided by operations in 2008 due primarily to anticipated declines in profitability levels in the current year. Our ability to generate cash during 2009 will depend, in part, on our ability to successfully sell our products and deliver our services, collect our accounts receivables, optimize lead times and inventory levels, and manage our expenses as well as other factors, such as possible acquisitions, which could use a significant amount of our existing cash and cash equivalents.

     Net cash used in investing activities for the three month period ended March 31, 2009 consisted primarily of payments for capital expenditures related to investments in information technology and new manufacturing equipment and tooling for products under development. Net cash flows used in investing activities for the three month period ended March 31, 2008 consisted of payments for capital expenditures related to new manufacturing equipment and tooling for products under development, partially offset by proceeds from maturities of short-term investments.

     Net cash provided by financing activities for the three month periods ended March 31, 2009 and 2008, respectively, consisted of proceeds from exercises of stock options and sales of common stock under our Employee Stock Purchase Plan less required minimum tax withholdings on restricted stock awards remitted to taxing authorities.

     As of March 31, 2009, our cash and cash equivalents totaled $37.6 million. We anticipate that our existing cash and cash equivalents and future expected operating cash flow will be sufficient to meet operating expenses, working capital requirements, capital expenditures and other obligations for at least 12 months.

     We have a $10.0 million line of credit with Silicon Valley Bank with minimal restrictions on the amount eligible for borrowing. Substantially all of our current assets were pledged as collateral for the line of credit. At March 31, 2009, we did not have any borrowings under this or any other line of credit.

     We may be affected by economic, financial, competitive, legislative, regulatory, business and other factors beyond our control. For more information on the factors that may impact our financial results, please see the Risk Factors included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2009. In addition, we are continually considering other acquisitions that complement or expand our existing business or that may enable us to expand into new markets. Future acquisitions may require additional debt, equity financing or both. We may not be able to obtain any additional financing, or may not be able to obtain additional financing on acceptable terms.

     Item 3. Quantitative and Qualitative Disclosures About Market Risk

     We develop products in the U.S. and sell them worldwide. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets. Since the majority of our revenues are currently priced in U.S. dollars and are translated to local currency amounts, a strengthening of the dollar could make our products less competitive in foreign markets.

     Item 4. Controls and Procedures

     Our chief executive officer and chief financial officer evaluated our disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q and have determined that our disclosure controls and procedures are effective to ensure that information required to be disclosed in our filings under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. In addition, our chief executive officer and chief financial officer concluded as of the end of the period covered by this quarterly report on Form 10-Q that our disclosure controls and procedures are effective to ensure that information required to be disclosed in reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer, to allow timely decisions regarding required disclosure.

     There were no changes in our internal control over financial reporting that occurred during our fiscal quarter ended March 31, 2009 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Page 23 of 29

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

     We are subject to various other legal proceedings arising in the normal course of business. In the opinion of management, the ultimate resolution of these proceedings is not expected to have a material effect on our consolidated financial position, results of operations or cash flows.

Item 1A. Risk Factors

     There have been no material changes that we are aware of from the risk factors set forth in Part I, Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission on March 16, 2009.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

     None.

Item 3. Defaults Upon Senior Securities

     None.

Item 4. Submission of Matters to a Vote of Security Holders

     None.

Item 5. Other Information

     None.

Item 6. Exhibits

No.		Description
	10.1	Master Agreement for Professional Services dated as of May 29, 2008 between Cardiac Science Corporation and Syncroness, Inc.
	10.2	Consulting Agreement dated as of March 26, 2009 between Cardiac Science Corporation and John R. Hinson.
	31.1	Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
	31.2	Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
	32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Page 24 of 29

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CARDIAC SCIENCE CORPORATION
By:	/s/ Michael K. Matysik
	Michael K. Matysik
	Senior Vice President and Chief Financial Officer (Principal Financial Officer)
	Date: May 8, 2009

Page 25 of 29